Thrombocytopenia As an Inexpensive, Valuable Predictor for Survival in Patients with Hepatocellular Carcinoma.
Qing Pang,Jing-Yao Zhang,Si-Dong Song,Kai Qu,Xin-Sen Xu,Su-Shun Liu,Ming-Hui Tai,Hao-Chen Liu,Chang Liu
DOI: https://doi.org/10.3109/00365521.2014.962076
2014-01-01
Scandinavian Journal of Gastroenterology
Abstract:Platelets are involved in liver regeneration and hepatic diseases via releasing several cytokines, including 5-hydroxytryptamine, platelet-derived growth factors and so forth. Due to splenic breakdown, a decrease in thrombopoietin production, and a capture of platelets by the liver [1], platelet count (PLT) generally reduces in cirrhotic patients. Furthermore, a PLT < 160 10/l significantly increased the risk of cirrhosis in patients with known/suspected liver disease [2]. In addition, thrombocytopenia/a low PLT was independently associated with hepatic carcinogenesis [3,4]. However, the association between PLT and prognosis of hepatocellular carcinoma (HCC) remains inconsistent and controversial. To explore the predictive significance of thrombocytopenia on survival of HCC patients who received surgical resection, we systematically searched PubMed, Embase and Web of Science until July 2014. We only included the studies whose PLT was expressed as binary variable. The primary outcomes were overall survival (OS) and recurrence-free survival (RFS) (or disease-free survival). Finally, we identified nine eligible publications, which consisted of 1434 men and 519 women (Table I). Among these, six reported hazard ratio (HR) value for OS and six studies were available to assess RFS. The cutoff value of PLT ranged from 100 to 150 ( 10/l). By pooling these studies (with adjusted HR, if available) using a random effects model, we found that preoperative thrombocytopenia was a significant predictor of short postoperative survival, with a HR value 1.51 (95% CI, 1.15–1.97, I 43.4%, p = 0.116) for OS and 1.44 (95% CI, 1.04–1.99, I 72.1%, p = 0.003) for RFS. By contrast, a significant relation was also observed between thrombocytopenia and outcome of HCC when we used a fixed effects model. Impact analysis was carried out, and it suggested that no single study could affect the results. In addition, we found no significant evidence of publication bias (a p value for OS and RFS 0.188, 0.133 in Begg’s test and 0.624, 0.201 in Egger’s test, respectively). We suggested that preoperative thrombocytopenia was an unfavorable factor for the prognosis of HCC. However, Buergy et al. [5] emphasized that thrombocytosis at the time of diagnosis was associated with a shorter survival in several solid tumors, including HCC. Shen et al. [6] suggested that patients with a preoperative PLT level ‡300 10/l had a worse OS (p = 0.020) as well as RFS (p = 0.009) compared with patients with a low level. In vitro, platelets could stimulate cell growth, migration and invasion, as well as increase AFP levels in several HCC cell lines [7]. These findings indicated that excessive platelets might induce a poor prognosis as well. Therefore, not only was thrombocytopenia a crucial predisposing factor for HCC occurrence, but it was also a helpful, readily available and inexpensive indictor to predict survival in individuals with HCC. However, more studies are needed to elucidate the exact mechanism of the relationship between PLT and HCC outcome.